Who are LAYLA tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trintellix, Fetzima, Pristiq, Celexa, Plavix, Racemic Sibutramine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/layla-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

LAYLA tablet — Competitive Intelligence Brief

LAYLA tablet (LAYLA tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SSRI. Area: Psychiatry.

marketed SSRI Serotonin transporter Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

LAYLA tablet (LAYLA tablet) — PMG Pharm Co., Ltd. LAYLA tablet is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LAYLA tablet TARGET	LAYLA tablet	PMG Pharm Co., Ltd	marketed	SSRI	Serotonin transporter
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Fetzima	LEVOMILNACIPRAN	AbbVie	marketed	Serotonin and Norepinephrine Reuptake Inhibitor	Sodium-dependent serotonin transporter	2013-01-01
Pristiq	desvenlafaxine	Alembic Pharms Ltd	marketed	Serotonin and Norepinephrine Reuptake Inhibitor	Sodium-dependent serotonin transporter	2008-01-01
Celexa	CITALOPRAM	AbbVie	marketed	Serotonin Reuptake Inhibitor	Sodium-dependent serotonin transporter	1998-01-01
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	marketed	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Racemic Sibutramine	SIBUTRAMINE		marketed	Norepinephrine, Serotonin, and Dopamine Reuptake Inhibitor Anorectic	Sodium-dependent serotonin transporter	1997-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SSRI class)

Washington University School of Medicine · 2 drugs in this class
Astellas Pharma Inc · 1 drug in this class
Beni-Suef University · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Centre of Clinical Pharmacology, Hanoi Medical University · 1 drug in this class
Chonbuk National University Hospital · 1 drug in this class
EMS · 1 drug in this class
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 1 drug in this class
PMG Pharm Co., Ltd · 1 drug in this class
PT Bio Farma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LAYLA tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/layla-tablet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab